A novel method for the large-scale production of PG-CNP37, a C-type natriuretic peptide analogue.

Autor: Long S; BioMarin Pharmaceutical, Inc., Novato, CA 94949, USA. slong@bmrn.com, Wendt DJ, Bell SM, Taylor TW, Dewavrin JY, Vellard MC
Jazyk: angličtina
Zdroj: Journal of biotechnology [J Biotechnol] 2012 Dec 15; Vol. 164 (2), pp. 196-201. Date of Electronic Publication: 2012 Aug 28.
DOI: 10.1016/j.jbiotec.2012.08.001
Abstrakt: Achondroplasia is the most common form of human dwarfism caused by a mutation in the fibroblast growth factor receptor 3 (FGFR3), resulting in abnormal endochondral bone formation. C-type natriuretic peptide (CNP) is a potent stimulator of endochondral bone growth and represents a potential therapy for achondroplasia. We have developed a novel, simple and cost effective method to produce a CNP analogue, PG-CNP37, at a large scale from Escherichia coli. A PG-CNP37 fusion protein was over-expressed as inclusion bodies in E. coli, which were purified then cleaved by formic acid to release the PG-CNP37 peptide. Approximately 0.5g of 95% pure, soluble and active PG-CNP37 peptide was produced from 1L of culture using this method and may represent a viable means for large-scale production of other therapeutic peptides.
(Copyright © 2012 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: